These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38675393)

  • 21. Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches.
    Rehman HM; Sajjad M; Ali MA; Gul R; Naveed M; Aslam MS; Shinwari K; Bhinder MA; Ghani MU; Saleem M; Rather MA; Ahmad I; Amin A
    Int J Biol Macromol; 2023 May; 237():124169. PubMed ID: 36990409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.
    Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M
    BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unravels the Influences of SARS-CoV-2 Infections to Cancer Patients.
    Chen Y; Qin Y; Fu Y; Gao Z; Deng Y
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the Binding Interaction of Active Compound of Pineapple against Foodborne Bacteria and Novel Coronavirus (SARS-CoV-2) Based on Molecular Docking and Simulation Studies.
    Abuzinadah MF; Ahmad V; Al-Thawdi S; Zakai SA; Jamal QMS
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19: docking-based virtual screening and molecular dynamics study to identify potential SARS-CoV-2 spike protein inhibitors from plant-based phenolic compounds.
    Moradkhani S; Farmani A; Saidijam M; Taherkhani A
    Acta Virol; 2021; 65(3):288-302. PubMed ID: 34565157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease.
    Zhang W; Liu L; Xiao X; Zhou H; Peng Z; Wang W; Huang L; Xie Y; Xu H; Tao L; Nie W; Yuan X; Liu F; Yuan Q
    Front Immunol; 2023; 14():961642. PubMed ID: 37026010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction Between SARS-CoV-2 and Pathogenic Bacteria.
    Fazel P; Sedighian H; Behzadi E; Kachuei R; Imani Fooladi AA
    Curr Microbiol; 2023 May; 80(7):223. PubMed ID: 37222840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations.
    Arshia AH; Shadravan S; Solhjoo A; Sakhteman A; Sami A
    Comput Biol Med; 2021 Dec; 139():104967. PubMed ID: 34739968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies.
    Azeem M; Mustafa G; Mahrosh HS
    Int J Immunopathol Pharmacol; 2022; 36():3946320221142793. PubMed ID: 36442514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Relationship Between Pediatric Gut Microbiota and SARS-CoV-2 Infection.
    Romani L; Del Chierico F; Macari G; Pane S; Ristori MV; Guarrasi V; Gardini S; Pascucci GR; Cotugno N; Perno CF; Rossi P; Villani A; Bernardi S; Campana A; Palma P; Putignani L;
    Front Cell Infect Microbiol; 2022; 12():908492. PubMed ID: 35873161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches.
    Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ
    F1000Res; 2021; 10():127. PubMed ID: 33968364
    [No Abstract]   [Full Text] [Related]  

  • 39. Bioinformatics screening of colorectal-cancer causing molecular signatures through gene expression profiles to discover therapeutic targets and candidate agents.
    Horaira MA; Islam MA; Kibria MK; Alam MJ; Kabir SR; Mollah MNH
    BMC Med Genomics; 2023 Mar; 16(1):64. PubMed ID: 36991484
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Br B; Damle H; Ganju S; Damle L
    F1000Res; 2020; 9():663. PubMed ID: 32765844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.